Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy
Authors
Keywords
-
Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume -, Issue -, Pages 1-7
Publisher
Informa UK Limited
Online
2020-06-23
DOI
10.1080/03007995.2020.1786681
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis
- (2019) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- ACG Clinical Guideline
- (2019) David T. Rubin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting
- (2019) Mayara Costa de Camargo et al. Frontiers in Pharmacology
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)
- (2018) Caterina Palleria et al. PLoS One
- Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation
- (2017) Christian Leporini et al. Expert Opinion On Drug Safety
- FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients
- (2017) Nicola S. Fracchiolla et al. HEMATOLOGICAL ONCOLOGY
- Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
- (2017) Bruce E. Sands et al. INFLAMMATORY BOWEL DISEASES
- Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study
- (2017) Cristina Scavone et al. Frontiers in Pharmacology
- Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
- (2015) K. Papamichael et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Biologic agents for IBD: practical insights
- (2015) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- The global burden of IBD: from 2015 to 2025
- (2015) Gilaad G. Kaplan Nature Reviews Gastroenterology & Hepatology
- The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper
- (2014) Gionata Fiorino et al. AUTOIMMUNITY REVIEWS
- Inflammatory bowel disease: Pathogenesis
- (2014) Yi-Zhen Zhang WORLD JOURNAL OF GASTROENTEROLOGY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- The burden of inflammatory bowel disease in Europe
- (2013) Johan Burisch et al. Journal of Crohns & Colitis
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More